Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ALX-0600 (NPS Allelix Corp).

¹University of Calgary, Pediatric General Surgeon, Department of Surgery, Canada. sigalet@ucalgary.ca

Current Opinion in Investigational Drugs (London, England : 2000)

|September 22, 2001

Summary

NPS Allelix is developing ALX-0600, a glucagon-like peptide 2 (GLP-2) analog, for gastrointestinal diseases like short bowel syndrome. The drug aims to increase intestinal absorptive area and received Orphan Drug designation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions.

Seminars in pediatric surgery·2018

Same author

Effects of sleeve gastrectomy and ileal transposition, alone and in combination, on food intake, body weight, gut hormones, and glucose metabolism in rats.

American journal of physiology. Endocrinology and metabolism·2013

Same author

Nonruminant Nutrition Symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander?

Journal of animal science·2011

Same author

The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation.

Neurogastroenterology and motility·2010

Same author

Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.

Digestive diseases and sciences·2006

Same author

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

American journal of physiology. Gastrointestinal and liver physiology·2004

Area of Science:

Gastroenterology
Pharmacology
Drug Development

Background:

Glucagon-like peptide 2 (GLP-2) analogs stimulate small intestine growth, enhancing nutrient absorption.
NPS Allelix is developing ALX-0600, a GLP-2 analog, for gastrointestinal diseases.

Purpose of the Study:

To evaluate ALX-0600 for treating short bowel syndrome (SBS).
To assess ALX-0600's potential in managing mucositis and inflammatory bowel disease.

Main Methods:

Pilot Phase II trials initiated in Q3 1999 for short bowel syndrome.
Pivotal Phase II trials commenced in 2000 to assess safety, tolerability, and efficacy.
FDA Orphan Drug designation was granted in August 1999.

Main Results:

The pilot trial focused on safety, tolerability, and drug-related improvements in nutrient absorption and gut changes.
Further results from ongoing trials are pending.

Conclusions:

ALX-0600 shows promise for treating short bowel syndrome and related gastrointestinal conditions.
NPS Allelix aims for market launch by 2001, with ongoing development and marketing discussions.

Related Experiment Videos